524723

Arvaya Healthcare Limited notified that due to an increase in its paid-up equity share capital on March 4, 2026, it no longer qualifies for the exemption under Regulation 15(2)(a) of SEBI LODR Regulations. Consequently, enhanced corporate governance provisions, including the Annual Secretarial Compliance Report, are now applicable. The company is taking necessary steps to comply within six months from the date of exceeding the threshold limit.

Arvaya Healthcare Limited reported Audited Standalone Financial Results for Q4 FY26. Total Income for the quarter was ₹6.61 Lacs, a ▲30.12% YoY increase from ₹5.08 Lacs. However, the company's EBITDA loss significantly widened to ₹69.96 Lacs from ₹18.81 Lacs in Q4 FY25. Net Loss (PAT) also widened to ₹63.35 Lacs from ₹20.52 Lacs YoY. The board also noted the resignation of its Internal Auditor and approved a new appointment.

Arvaya Healthcare Limited's Board Meeting on May 28, 2026, approved audited financial results (Standalone and Consolidated) for Q4 and FY ended March 31, 2026, with an unmodified audit opinion. Key updates include the company's name change from Bijoy Hans Limited, an increase in authorized share capital from ₹60 Cr to ₹200 Cr, and the acquisition of three subsidiaries (Health Secure Hospitals, Arvaya Health and Wellness, Tec-Pool Solutions) for approximately ₹606.5 Cr. These acquisitions, effective March 4, 2026, significantly change the company's composition. An internal auditor resigned and a new one was appointed.

Arvaya Healthcare Limited reported Standalone Revenue from operations ₹0.00 Lacs vs ₹0.36 Lacs (▼100% YoY), EBITDA ₹(69.96) Lacs vs ₹(18.81) Lacs (loss widened), PAT ₹(63.35) Lacs vs ₹(20.52) Lacs (loss widened). EBITDA Margin not meaningful due to negative EBITDA. The Board also noted the resignation of Mr. Aslesh Ramchandra Parannawar as Internal Auditor and appointed M/s. G K Vora & Co. as replacement.

Arvaya Healthcare Limited announced a Board Meeting to be held on Thursday, May 28, 2026, to consider and approve the Audited Financial Statements (Standalone and Consolidated) for the Fourth Quarter and Year Ended March 31, 2026. The trading window for dealing in shares remains closed from April 01, 2026, to May 30, 2026.